Moderna announced the development of a single vaccine that protects from COVID-19 and seasonal flu. Reports about it Reuters.
According to the representative of Moderna, the company’s main priority is to bring the vaccine against respiratory diseases to the market. Developers intend to constantly update the composition of the vaccine in accordance with common strains. The combined drug can be entered once, but the timing of its launch is not communicated.
Another American company NOVAVAX is behaved like this development. The company has already conducted a testing of polyvaccines and are preparing to begin a mass release.
Moderna has declared the development of its own RNA-vaccine against the SARS-COV-2 virus in January 2020. The third test stage ended in November 2020, and in December, the results were published in the review magazine. The effectiveness of the drug amounted to 94.1 percent, and for people over 65 – 86.4.
Despite the small number of negative consequences, in 2021, the Food and Drug Administration (FDA) and the Centers for the Control and Prevention of Diseases of the United States (CDC) began an investigation after reports on hazardous implications.